{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:08:24Z","timestamp":1774951704490,"version":"3.50.1"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Takeda Mexico, S.A. de C.V."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Crohn\u2019s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) that have a negative impact on patient quality of life (QOL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate QOL, work productivity, use of healthcare resources, and medical costs in patients with IBD from the RISE-MX trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>RISE-MX was a non-interventional, multicentric, cross-sectional, retrospective study conducted in a Mexican population with IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The 36-item Short Form Health Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ) were used to assess QOL. The burden of disease was analyzed using the Work Productivity and Activity Impairment Questionnaire (WPAI), healthcare resources use, and medical costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 326 subjects, 95 (29.1%) had CD, and 231 (70.8%) had UC. In patients with CD, 43 patients (45.3%) showed moderate-to-severe activity, and 42 (18.1%) had moderate-to-severe disease activity in patients with UC. In all SF-36 dimensions, a significant difference between moderate-to-severe and mild activity\/in remission groups was observed in patients with UC, while in patients with CD, the difference between activity groups was significant only for physical functioning and social functioning dimensions. In patients with CD, a higher but non-significant IBDQ score difference between activity groups was observed while a statistical difference between activity groups was observed for all dimensions in UC patients. In WPAI, the total percentage for work impairment (absenteeism plus presenteeism) and the percentage of regular daily activity impairment were statistically significant between activity groups only for UC. The annual total costs (direct and indirect) per patient in CD were USD 19,757 (moderate-to-severe activity group) and USD 12,587 (mild activity\/in remission group), while in patients with UC were USD 11,702 and USD 9144, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Moderate-to-severe activity of disease was associated with a substantial impact on QOL, work productivity, and medical costs in Mexican patients with IBD. Total costs were higher for patients with CD than for patients with UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848251318032","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T03:08:37Z","timestamp":1742353717000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Quality of life and burden of disease in a Mexican population with inflammatory bowel disease: an analysis of the RISE-MX trial"],"prefix":"10.1177","volume":"18","author":[{"given":"Rosa M.","family":"Miranda-Cordero","sequence":"first","affiliation":[{"name":"Clinica de Enfermedad Inflamatoria Intestinal, Centro M\u00e9dico ISSEMyM, Estado de M\u00e9xico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Bosques-Padilla","sequence":"additional","affiliation":[{"name":"Departamento de Gastroenterolog\u00eda, Hospital Universitario, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Nuevo Le\u00f3n, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel Alejandro","family":"Mart\u00ednez-V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Tecnol\u00f3gico de Monterrey, Escuela de Medicina y Ciencias de la Salud Monterrey, Monterrey, Nuevo Le\u00f3n, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Barajas-Maldonado","sequence":"additional","affiliation":[{"name":"Medical Affairs, Takeda M\u00e9xico, Ciudad de M\u00e9xico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio M.","family":"Rodriguez-Mendoza","sequence":"additional","affiliation":[{"name":"Health Economics Outcomes Research, Takeda M\u00e9xico, Ciudad de M\u00e9xico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-5812","authenticated-orcid":false,"given":"Jes\u00fas K.","family":"Yamamoto-Furusho","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Vasco de Quiroga 15, Colonia Belisario Dom\u00ednguez Secci\u00f3n XVI, Tlalpan, Mexico City 14080, Mexico"},{"name":"Cl\u00ednica de Enfermedad Inflamatoria Intestinal, Departamento de Gastroenterolog\u00eda, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Ciudad de M\u00e9xico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v11i1.3135"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60751-X"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2018-0075"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251318857"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac187"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.082909"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.01.003"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/269076"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes13122388"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab029"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6542a3"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12317"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i30.4174"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.06.030"},{"key":"e_1_3_4_16_2","article-title":"The impact of inflammatory bowel disease in Canada 2018: epidemiology","volume":"2","author":"Kaplan GG","year":"2019","unstructured":"Kaplan GG, Bernstein CN, Coward S, et al. The impact of inflammatory bowel disease in Canada 2018: epidemiology. J Can Assoc Gastroenterol 2019; 2(Suppl. 1): S6\u2013S16.","journal-title":"J Can Assoc Gastroenterol"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-023-01944-2"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.06.030"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028624"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024729"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016291"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13847"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58040486"},{"issue":"8","key":"e_1_3_4_24_2","first-page":"1571","article-title":"The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial","volume":"91","author":"Irvine EJ","year":"1996","unstructured":"Irvine EJ, Zhou Q, Thompson AK. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial. Am J Gastroenterol 1996; 91(8): 1571\u20131578.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.02.016"},{"issue":"9","key":"e_1_3_4_26_2","article-title":"The impact of biological interventions for ulcerative colitis on health-related quality of life","volume":"2015","author":"LeBlanc K","year":"2015","unstructured":"LeBlanc K, Mosli MH, Parker CE, et al. The impact of biological interventions for ulcerative colitis on health-related quality of life. Cochrane Database Syst Rev 2015; 2015(9): CD008655.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20166576"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac145"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033713"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz024"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13060947"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1590\/0102-672020210002e1653"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5354320"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2018.00099"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i38.5862"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000525206"},{"issue":"2","key":"e_1_3_4_37_2","first-page":"213","article-title":"Frequency of use and cost of biologic treatment for inflammatory bowel disease and inflammatory bowel disease-associated arthropathy in Colombia in 2019","volume":"89","author":"Fern\u00e1ndez-\u00c1vila DG","year":"2024","unstructured":"Fern\u00e1ndez-\u00c1vila DG, D\u00e1vila-Ruales V. Frequency of use and cost of biologic treatment for inflammatory bowel disease and inflammatory bowel disease-associated arthropathy in Colombia in 2019. Rev Gastroenterol Mex (Engl Ed) 2024; 89(2): 213\u2013221.","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"e_1_3_4_38_2","article-title":"The impact of inflammatory bowel disease in Canada 2018: direct costs and health services utilization","volume":"2","author":"Kuenzig ME","year":"2019","unstructured":"Kuenzig ME, Benchimol EI, Lee L, et al. The impact of inflammatory bowel disease in Canada 2018: direct costs and health services utilization. J Can Assoc Gastroenterol 2019; 2(Suppl. 1): S17\u2013S33.","journal-title":"J Can Assoc Gastroenterol"},{"key":"e_1_3_4_39_2","article-title":"The impact of inflammatory bowel disease in Canada 2018: indirect costs of IBD care","volume":"2","author":"Kuenzig ME","year":"2019","unstructured":"Kuenzig ME, Lee L, El-Matary W, et al. The impact of inflammatory bowel disease in Canada 2018: indirect costs of IBD care. J Can Assoc Gastroenterol 2019; 2(Suppl. 1): S34\u2013S41.","journal-title":"J Can Assoc Gastroenterol"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac144"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02473-6"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231167953"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12262"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i9.872"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20520"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302311"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.01.010"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251318032","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848251318032","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251318032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:14:36Z","timestamp":1767687276000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848251318032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":47,"alternative-id":["10.1177\/17562848251318032"],"URL":"https:\/\/doi.org\/10.1177\/17562848251318032","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"article-number":"17562848251318032"}}